Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00773786 · ClinicalTrials.gov registry record · Phase 4
Effect of Brovana and Tiotropium in Chronic Obstructive Pulmonary Disease (COPD)
A Phase 4 study of COPD, sponsored by Trinity Health Of New England.
- Completed
- Registry status
- Phase 4
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT00773786 is a Phase 4 study of COPD that has completed, run by Trinity Health Of New England. The registered enrollment target is 20 participants, below the 2,418-participant average among 85 other COPD trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00773786, a Phase 4 study of COPD, has completed, sponsored by Trinity Health Of New England.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
This will be a double-blind crossover trial in 20 patient with stable COPD. Data from this study will provide proof-of-concept information on whether the (anticipated) additional bronchodilator effect of Brovana added to tiotropium will lead to a meaningful improvement in the patient-centered outcome, exercise capacity. This study will only evaluate the effects of short-term (1-week) administration of Brovana. If results are positive, it would provide preliminary data for further, multicenter investigations.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Arformoterol (Brovana)
Study Locations (1)
Connecticut
- St Francis Hospital and Medical center - Hartford
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2008-10 |
| Est. Completion | 2009-05 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00773786
The ClinicalTrials.gov registry entry for NCT00773786 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,418-participant average among 85 other COPD trials with a reported enrollment target (99% lower). The listed sponsor is Trinity Health Of New England, which has 20 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with COPD appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT00773786 reports 1 study location spanning 1 distinct geographic area - top geographies include Connecticut.
Frequently Asked Questions
What is clinical trial NCT00773786 about?
NCT00773786 is a clinical study titled "Effect of Brovana and Tiotropium in Chronic Obstructive Pulmonary Disease (COPD)". This will be a double-blind crossover trial in 20 patient with stable COPD. Data from this study will provide proof-of-concept information on whether the (anticipated) additional bronchodilator effect of Brovana added to tiotropium will lead to a meaningful improvement in the patient-centered outcom...
What is the current status of trial NCT00773786?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 20 participants. The study started on 2008-10. Estimated completion is 2009-05.
What conditions does trial NCT00773786 study?
This clinical trial studies the following conditions: COPD.
What interventions are being tested in trial NCT00773786?
The interventions under investigation include: Placebo (DRUG), Arformoterol (Brovana) (DRUG).
Who is sponsoring clinical trial NCT00773786?
This trial is sponsored by Trinity Health Of New England, which has 20 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00773786 being conducted?
This trial has 1 study location across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for COPD
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Genetic Variation in IgG in Alpha 1 Antitrypsin Deficiency
RECRUITING · Phase 4
-
The Effects of Positive Airway Pressure on the Mucolytic Effects of NAC (TEAM)
RECRUITING · Phase 4
-
Peak Inspiratory Flow and Dry Powder Inhaler Performance in COPD
COMPLETED · Phase 4
-
Static Lung Hyperinflation and Sympathetic Nerve Activity-Associated Large Artery Stiffness in COPD Patients
COMPLETED · Phase 4
-
Airway Clearance for Prevention of Chronic Obstructive Pulmonary Disease (COPD) Exacerbation
COMPLETED · Phase 4
-
Evaluate the Effect of Aclidinium Bromide on Long-term Cardiovascular Safety and Exacerbations in Moderate to Very Severe COPD Patients.
COMPLETED · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.